Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:1781
Name thyroid cancer
Definition An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.
Source DiseaseOntology.org
Alt Ids DOID:10008
Path disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer thyroid cancer

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF mutant Selumetinib thyroid cancer predicted - sensitive detail...
NRAS mutant Selumetinib thyroid cancer sensitive detail...
BRAF V600E Lapatinib + Vemurafenib thyroid cancer sensitive detail...
HRAS inact mut Dactolisib thyroid cancer sensitive detail...
FGFR1 over exp Lenvatinib thyroid cancer sensitive detail...
RET C634W Lenvatinib thyroid cancer sensitive detail...
BRAF V600X Vemurafenib thyroid cancer predicted - sensitive detail...
BRAF V600E CLM3 thyroid cancer sensitive detail...
BRAF wild-type CLM3 thyroid cancer sensitive detail...
BRAF V600E Lifirafenib thyroid cancer predicted - sensitive detail...
RET C634W Regorafenib thyroid cancer sensitive detail...
BRAF V600E Trametinib thyroid cancer predicted - sensitive detail...
BRAF V600E Selumetinib thyroid cancer sensitive detail...
BRAF V600E Dasatinib + Trametinib thyroid cancer sensitive detail...
BRAF V600E Dasatinib + Selumetinib thyroid cancer sensitive detail...
BRAF V600E Dasatinib + SCH772984 thyroid cancer sensitive detail...
BRAF V600E TAK-632 thyroid cancer sensitive detail...
BRAF V600E Vemurafenib thyroid cancer conflicting detail...
RET C634W AZD1480 thyroid cancer sensitive detail...
PIK3CA H1047R MK2206 thyroid cancer sensitive detail...
HRAS G13R MK2206 thyroid cancer sensitive detail...
NRAS Q61R MK2206 thyroid cancer sensitive detail...
PIK3CA E545K MK2206 thyroid cancer sensitive detail...
PIK3CA H1047R MK2206 + Temsirolimus thyroid cancer sensitive detail...
BRAF mutant Belvarafenib thyroid cancer sensitive detail...
RET fusion Selpercatinib thyroid cancer sensitive detail...
BRAF V600E PLX4720 + Ponatinib thyroid cancer sensitive detail...
BRAF V600E Ponatinib + Vemurafenib thyroid cancer sensitive detail...
RET fusion Pralsetinib thyroid cancer sensitive detail...
BRAF V600E Dabrafenib + SCH772984 thyroid cancer sensitive detail...
RET C634W APS03118 thyroid cancer predicted - sensitive detail...
NRAS Q61K Everolimus + RO5126766 thyroid cancer predicted - sensitive detail...
HRAS G13R Trametinib thyroid cancer sensitive detail...
HRAS G13R Dasatinib + Trametinib thyroid cancer sensitive detail...
HRAS G13R Selumetinib thyroid cancer sensitive detail...
HRAS G13R Dasatinib + Selumetinib thyroid cancer sensitive detail...
RET C634W TY-1091 thyroid cancer predicted - sensitive detail...
ATM L2738* Radiotherapy thyroid cancer predicted - sensitive detail...
NRAS Q61K IHMT-RAF-128 thyroid cancer sensitive detail...
BRAF V600E SHP099 + Vemurafenib thyroid cancer sensitive detail...
PTEN L194fs Ipilimumab + Nivolumab + Temsirolimus thyroid cancer predicted - sensitive detail...
BRAF V600E Binimetinib + Encorafenib thyroid cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01182285 Phase II Liothyronine sodium Valproic acid A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin Completed USA 0
NCT01236547 Phase II Paclitaxel Pazopanib Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer Completed USA 0
NCT01240590 Phase Ib/II Cisplatin + Crolibulin Cisplatin A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) Completed USA 0
NCT01263951 Phase II Everolimus + Sorafenib Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone Unknown status USA 0
NCT01270321 Phase II Pasireotide Everolimus A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer Completed USA 0
NCT01438554 Phase I Pazopanib + Trametinib Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Completed USA 0
NCT01543763 Phase I Panobinostat + Pazopanib Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors Active, not recruiting USA 0
NCT01811212 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Completed USA 0
NCT01843062 Phase III Selumetinib Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer Terminated USA | ITA | FRA | DEU 4
NCT01876784 Phase III Vandetanib Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer Completed USA | ITA | FRA | ESP 8
NCT01947023 Phase I Dabrafenib + Lapatinib Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT02012231 Phase Ib/II PLX8394 Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. Terminated USA 0
NCT02034110 Phase II Dabrafenib + Trametinib Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Completed USA | NLD | ITA | FRA | ESP | DEU | CAN | BEL | AUT 5
NCT02041260 Phase II Cabozantinib A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting Unknown status USA 0
NCT02143726 Phase II Sorafenib Everolimus Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Thyroid Cancer Active, not recruiting USA 0
NCT02244463 Phase II Sapanisertib A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer Completed USA 0
NCT02289144 Phase II Ceritinib Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer Withdrawn USA 0
NCT02383927 Phase II Tipifarnib Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL 2
NCT02432274 Phase Ib/II Etoposide Lenvatinib Cyclophosphamide Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies Completed USA | ITA | GBR | FRA | ESP | DEU 0
NCT02576431 Phase II Larotrectinib A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) Active, not recruiting USA | FRA | ESP | DEU 14
NCT02657369 Phase II Lenvatinib A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) Terminated USA | ITA | GBR | FRA | AUS 0
NCT02688608 Phase II Pembrolizumab Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Completed USA 0
NCT02721732 Phase II Pembrolizumab Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Active, not recruiting USA 0
NCT02973997 Phase II Lenvatinib + Pembrolizumab Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery Completed USA 0
NCT03002623 Phase II CUDC-907 CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer Terminated USA 0
NCT03085056 Phase I Paclitaxel + Trametinib Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer Active, not recruiting USA 0
NCT03099356 Phase II Cyclophosphamide + Sirolimus Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer Recruiting USA 0
NCT03122496 Phase I Durvalumab + Tremelimumab Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer Completed USA 0
NCT03131206 Phase Ib/II Alectinib A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer Terminated USA 0
NCT03139747 Phase II Everolimus + Lenvatinib UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone Suspended USA 0
NCT03157128 Phase Ib/II Selpercatinib A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 8
NCT03211117 Phase II Docetaxel + Doxorubicin + Pembrolizumab Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer Completed USA 0
NCT03246958 Phase II Ipilimumab + Nivolumab Nivolumab Plus Ipilimumab in Thyroid Cancer Active, not recruiting USA 0
NCT03360890 Phase II Docetaxel + Pembrolizumab Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors Recruiting USA 0
NCT03506048 Phase II Lenvatinib Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer Terminated USA 0
NCT03630120 Phase II Lenvatinib + Sorafenib Cabozantinib + Vandetanib Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer Terminated USA 0
NCT03690388 Phase III Cabozantinib A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 14
NCT03753919 Phase II Durvalumab + Tremelimumab Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY) Active, not recruiting ESP 0
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA | FRA | BEL | AUS 1
NCT03975231 Phase I Dabrafenib + Trametinib Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer Recruiting USA 0
NCT04061980 Phase II Binimetinib + Encorafenib Binimetinib + Encorafenib + Nivolumab Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer Recruiting USA 0
NCT04321954 Phase II Lenvatinib Lenvatinib in Locally Advanced Invasive Thyroid Cancer Recruiting USA 0
NCT04420754 Phase I AIC100 Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer Recruiting USA 0
NCT04552769 Phase II Abemaciclib Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer Active, not recruiting USA 0
NCT04682431 Phase I Pembrolizumab + PY159 PY159 A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Terminated USA 0
NCT04706962 Phase I TH1902 TH1902 in Patients With Advanced Solid Tumors Recruiting USA | CAN 0
NCT04940052 Phase III Dabrafenib + Trametinib Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer Recruiting USA | CAN 10
NCT05182931 Phase II Dabrafenib + Trametinib Trametinib A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) (I-FIRST) Recruiting AUS 0
NCT05275374 Phase Ib/II BI 882370 + Trametinib BI 882370 XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE) Not yet recruiting 0
NCT05652855 Phase Ib/II MHB088C Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05668962 Phase II Selpercatinib Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC Recruiting USA 0
NCT05718557 Phase I PYX-106 Study of PYX-106 in Solid Tumors Recruiting USA | ESP | BEL 0
NCT05720117 Phase I PYX-201 Study of PYX-201 in Solid Tumors Recruiting USA | ESP | BEL 0
NCT05785728 Phase Ib/II DB-1202 A Phase 1/2 Study of DB-1202 Monotherapy in Advanced Solid Tumors Not yet recruiting 1